Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 8/20 | 0.54 |
| ▸ | BRAF | P15056 | 7/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | IDH2 | P48735 | 5/20 | 0.51 |
| ▸ | ERN1 | O75460 | 3/20 | 0.51 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.49 |
| ▸ | AKT1 | P31749 | 1/20 | 0.49 |
| ▸ | CLK2 | P49760 | 1/20 | 0.49 |
| ▸ | GSK3A | P49840 | 1/20 | 0.49 |
| ▸ | GSK3B | P49841 | 1/20 | 0.49 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.49 |
| ▸ | STK3 | Q13188 | 1/20 | 0.49 |
| ▸ | HIPK4 | Q8NE63 | 1/20 | 0.49 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4464429 | 0.87 | PIK3CA (0.52) | KDM4EGAACLK2GSK3AGSK3B | |
| SCHEMBL27559838 | 0.86 | MAPK14 (0.54) | RAF1BRAFKDM4EGAACLK2 | |
| SCHEMBL28747223 | 0.85 | CLK2 (0.49) | RAF1BRAFKDM4EGAACLK2 | |
| SCHEMBL7069390 | 0.83 | EPHX2 (0.49) | RAF1BRAFKDM4EGAACLK2 | |
| SCHEMBL4456006 | 0.82 | MAPK1 (0.42) | BRAFKDM4EGAACLK2GSK3A | |
| SCHEMBL7070212 | 0.80 | MAPK14 (0.49) | RAF1BRAFKDM4EGAAAKT1 | |
| SCHEMBL7067699 | 0.80 | CNR1 (0.47) | KDM4ECLK2GSK3AGSK3BCSNK2A1 | |
| SCHEMBL7064948 | 0.78 | KDM4E (0.45) | KDM4EGAAAKT1CLK2GSK3A | |
| SCHEMBL6257285 | 0.78 | MTOR (0.41) | KDM4EGSK3A | |
| SCHEMBL5462710 | 0.78 | PIK3CA (0.40) | KDM4EAKT1CLK2GSK3AGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030225089-A1 | Pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225089-A1 | Pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors | CHRM3, CHRM2, CHRNB1 | RAF1 712/4885BRAF 2107/4885KDM4E 3817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.